Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aim: To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control. Materials and methods: A 26‐week, randomized, double‐blind, placebo‐controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment. The primary endpoint was change in haemoglobin A1c (HbA1c). Secondary endpoints included change in insulin dose, CSII settings, glycaemic variability, body weight and patient‐reported outcome measures. Finally, adverse effects including hypoglycaemic events were registered. Results: HbA1c was reduced by 5 mmol/mol (0.5%) from a baseline of 66 mmol/mol (8.2%) in patients treated with liraglutide compared with a non‐significant change of +2.3 mmol/mol (0.2%) from a baseline of 66 mmol/mol (8.1%) in patients treated with placebo (between‐group difference 7 mmol/mol [0.7%], P < 0.001). Liraglutide reduced total insulin dose by 8 units/day or 16% of total insulin dose ( P = 0.008). Mean body weight was reduced by 6.3 kg ( P < 0.001) compared with placebo. Concomitantly, time spent in glycaemic target range 4–10 mmol/L (71–180 mg/dL) increased while the risk of hypoglycaemia did not differ between groups at the end of treatment. Conclusion: Liraglutide treatment reduced HbA1c, total daily insulin dose and body weight without increasing the risk of hypoglycaemia in CSII‐treated patients with type 1 diabetes and insufficient glycaemic control. Liraglutide may be considered a potential add‐on therapy to insulin in this subgroup of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“Furthermore, the reduction in both insulin dose and bodyweight may be a consequence of the appetite-reducing effect of GLP-1 inducing a lower food volume and carbohydrate intake.(19) The direct effect of GLP-1RA on insulin resistance in peripheral tissue is limited and, if present, may be a result of reduction in adip…”
BackgroundMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“The T1D Exchange Clinic Registry reports that >55% of US adults with type 1 diabetes are currently treated with CSII and the number is increasing.(5,6) However, more than two-thirds of adults with type 1 diabetes do not achieve the recommended glycaemic target [haemoglobin A1c (HbA1c) <53 mmol/mol (7.”
BackgroundMathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Temporal patterns in overweight and obesity in type 1 diabetes
Conway, B., Miller, R. G., Costacou, T., Fried, L., Kelsey, S., Evans, R. W., & Orchard, T. J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02956.x · Cited by 326 · cited 1×
“Duration of type 1 diabetes (years) 21 (15; 34) 20 (15; 35)”
Obesity and health-related quality of life: a cross-sectional analysis of the US population
Hassan, M. K., Joshi, A. V., Madhavan, S. S., & Amonkar, M. M. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802396 · Cited by 314 · cited 1×
“We obtained a total reduction of 8% of body weight in persons treated with liraglutide, which is likely to be of clinical importance,(15) as weight loss has been reported to improve quality of life and insulin sensitivity, and reduce cardiovascular risk factors in people with type 1 diabetes.(16-18) Even though patien…”
BackgroundGastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273
Insulin-pump therapy for type 1 diabetes mellitus
Pickup, J. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1113948 · Cited by 270
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262 · cited 9×
“2020;22:492–500.wileyonlinelibrary.com/journal/dom type 1 diabetes in the industrialized part of the world are overweight, and interventions to prevent weight gain are strongly warranted.1,2 Compared with multiple daily injections (MDI) subcutaneous insulin infusion (CSII) therapy improves glycaemic control and reduce…”
BackgroundMethodResultInfluentialType 1 diabetes, metabolic syndrome and cardiovascular risk
Chillarón, J. J., Flores Le-Roux, J. A., Benaiges, D., & Pedro-Botet, J. (2014) · Metabolism · doi:10.1016/j.metabol.2013.10.002 · Cited by 195
Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103 · cited 9×
“2020;22:492–500.wileyonlinelibrary.com/journal/dom type 1 diabetes in the industrialized part of the world are overweight, and interventions to prevent weight gain are strongly warranted.1,2 Compared with multiple daily injections (MDI) subcutaneous insulin infusion (CSII) therapy improves glycaemic control and reduce…”
BackgroundMethodResultInfluentialSelf-citation
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Metadata
- Authors
- Dejgaard, T. F., Schmidt, S., Frandsen, C. S., Vistisen, D., Madsbad, S., Andersen, H. U., & Nørgaard, K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-12-19
- Volume
- 22
- Issue
- 4
- Pages
- 492-500
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2984584141
- Cited by
- 72
- References
- 13
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/dom.13911
- The paper
- Dejgaard, T. F., Schmidt, S., Frandsen, C. S., Vistisen, D., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2020). Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13911
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.